ArticleBiology of reproduction2018
Effects of histone methyltransferase inhibition in endometriosis.
Article in Biology of reproduction, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 32 citations in OpenAlex.
- Epigenetic mechanisms in maternal-fetal crosstalk: inter- and trans-generational inheritance.Epigenomics · 2025Review
- Dual targeting of CXCR4 and EZH2 in endometriosis.iScience · 2025Article
- EZH2 promotes endometriosis progression through estrogen receptor and TNFα expression.Frontiers in endocrinology · 2025Article
- The long road of drug development for endometriosis - Pains, gains, and hopes.Journal of controlled release : official journal of the Controlled Release Society · 2024Review
- Control of endothelial cell function and arteriogenesis by MEG3:EZH2 epigenetic regulation of integrin expression.Molecular therapy. Nucleic acids · 2024Article
- The roles of chromatin regulatory factors in endometriosis.Journal of assisted reproduction and genetics · 2024Review
- The involvement of RNA N6-methyladenosine and histone methylation modification in decidualization and endometriosis-associated infertility.Clinical and translational medicine · 2024Article
- A Systematic Review of Epigenetics of Endometriosis.F&S reviews · 2024Article
- Epigenetic Dysregulation in Endometriosis: Implications for Pathophysiology and Therapeutics.Endocrine reviews · 2023Review
- Decreased Expression of EZH2 in Granulosa Cells Contributes to Endometriosis-Associated Infertility by Targeting IL-1R2.Endocrinology · 2022Article
- AP-1 Subunit JUNB Promotes Invasive Phenotypes in Endometriosis.Reproductive sciences (Thousand Oaks, Calif.) · 2022Article
- Spatial transcriptomics analysis of uterine gene expression in enhancer of zeste homolog 2 conditional knockout mice†.Biology of reproduction · 2021Article
- The role of epigenetic mechanisms in the regulation of gene expression in the cyclical endometrium.Clinical epigenetics · 2021Review
- Peritoneal Modulators of EZH2-miR-155 Cross-Talk in Endometriosis.International journal of molecular sciences · 2021Article
- Endometriosis and ovarian cancer risk, an epigenetic connection.Annals of translational medicine · 2020Review
- Article
- Inhibition of Histone Methyltransferase EZH2 Suppresses Endometriotic Vesicle Development in a Rat Model of Endometriosis.Reproductive sciences (Thousand Oaks, Calif.) · 2020Article
- Dysregulation of miR-202-3p Affects Migration and Invasion of Endometrial Stromal Cells in Endometriosis via Targeting ROCK1.Reproductive sciences (Thousand Oaks, Calif.) · 2020Article
- Aberrant expression of histone deacetylase 8 in endometriosis and its potential as a therapeutic target.Reproductive medicine and biologyArticle
- Corroborating evidence for aberrant expression of histone deacetylase 8 in endometriosis.Reproductive medicine and biologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 2 countries.
Funding
Abstract
Although the histone methyltransferase EZH2 and its product H3K27me3 are well studied in cancer, little is known about their role and potential as therapeutic targets in endometriosis. We have previously reported that endometriotic lesions are characterized by global enrichment of H3K27me3. Therefore, we aimed to (1) characterize the expression levels of EZH2 in endometriotic tissues; (2) assess H3K27me3 enrichment in candidate genes promoter regions; and (3) determine if pharmacological inhibition of EZH2 impacts migration, proliferation, and invasion of endometriotic cells. Immunohistochemistry of an endometriosis-focused tissue microarray was used to assess the EZH2 protein levels in tissues. Chromatin immunoprecipitation-qPCR was conducted to assess enrichment of H3K27me3 in candidate gene promoter regions in tissues. Immunofluorescence was performed to assess the effect of an EZH2-specific pharmacological inhibitor on H3K27me3 global enrichment in cell lines. To measure effects of the inhibitor in migration, proliferation, and invasion in vitro we used Scratch, BrdU, and Matrigel assays, respectively. Endometriotic lesions had significantly higher EZH2α nuclear immunostaining levels compared to eutopic endometrium from patients (glands, stroma) and controls (glands). H3K27me3 was enriched within promoter regions of candidate genes in some but not all of the endometriotic lesions. Inhibition of EZH2 reduced H3K27me3 levels in the endometriotic cells specifically, and also reduced migration, proliferation but not invasion of endometriotic epithelial cells (12Z). These findings support future preclinical studies to determine in vivo efficacy of EZH2 inhibitors as promising nonhormonal treatments for endometriosis, still an incurable gynecological disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.